Core Viewpoint - China National Pharmaceutical Group Co., Ltd. announced the approval of fumaric acid volnorelaxin tablets by the National Medical Products Administration, marking a significant step in the company's integrated layout of raw materials and formulations [1] Group 1: Product Approval and Specifications - The approved specifications for the drug are 10mg and 20mg, primarily used for treating reflux esophagitis and eradicating Helicobacter pylori in conjunction with antibiotics [1] - The total investment in the raw material and formulation project for this drug amounts to approximately 12.32 million RMB [1] Group 2: Market Potential and Sales Forecast - According to data from Minet, the estimated sales revenue for this drug in China's three major terminal markets is approximately 774 million RMB in 2024, with sales of about 778 million RMB in the first three quarters of 2025 [1] - Currently, a total of 40 production enterprises, including Tianfang Pharmaceutical, have obtained approval for this drug [1] Group 3: Strategic Implications - The approval is expected to enrich the company's product line and enhance its business layout [1] - Future sales performance may be influenced by uncertainties related to national policies and market conditions [1]

Roche (OTCPK:RHHB.F) Conference Call Summary Company Overview - **Company**: Roche - **Focus**: Neurology, specifically Multiple Sclerosis (MS) treatments - **Key Products**: Ocrevus (ocrelizumab), fenebrutinib Core Industry Insights - **Multiple Sclerosis (MS)**: A significant unmet medical need exists, with approximately 30% of patients on low-efficacy treatments and continuing to progress [10][11] - **Treatment Paradigm**: Ocrevus has revolutionized MS treatment since its launch in 2017, being the first and only twice-yearly anti-CD20 approved for both relapsing and primary progressive MS (PPMS) [5][6] Key Points from the Call Fenebrutinib Development - **Phase 3 FENtrepid Results**: Fenebrutinib has shown non-inferiority to ocrelizumab in reducing disability progression in PPMS, with a 12% risk reduction in confirmed disability progression [24][25] - **Mechanism of Action**: Fenebrutinib is a non-covalent BTK inhibitor that addresses both relapsing and progressive MS biology, potentially impacting disability accumulation [13][39] - **Clinical Trial Design**: The FENtrepid study was a multicenter, randomized, double-blind trial comparing fenebrutinib to ocrelizumab, with a primary endpoint of confirmed disability progression [19][20] Ocrevus Franchise Update - **Current Usage**: Over 450,000 patients are currently treated with Ocrevus, which remains the leading new-to-brand medicine in MS [5][6] - **Ocrevus Zunovo**: A new subcutaneous formulation has shown significant uptake, contributing to over 50% of global growth in Q4 2025, with a projected CHF 2 billion incremental sales opportunity by 2029 [6][7] Safety and Efficacy - **Safety Profile**: Fenebrutinib showed a higher incidence of liver enzyme elevations compared to ocrelizumab, with 14% of patients in the fenebrutinib arm withdrawing due to adverse events, primarily related to liver enzyme elevations [30][34] - **Fatal Events**: There were more fatal events in the fenebrutinib arm (7) compared to ocrelizumab (1), but investigators assessed these as unrelated to the study drug [31][32] Future Outlook - **Pipeline Expansion**: Roche is advancing multiple molecules in neurology, including prasinezumab for Parkinson's and trontinemab for Alzheimer's, alongside fenebrutinib [10][12] - **High-Concentration Ocrevus**: A new formulation with an on-body injector is expected to launch in 2028, allowing for home administration [7][8] Additional Insights - **Market Positioning**: Fenebrutinib is positioned as a first-in-class oral therapy for both PPMS and relapsing MS, providing an alternative for patients who may not tolerate or have access to infusions [60][61] - **Clinical Practice**: The majority of patients in clinical practice are currently on ocrelizumab, with ongoing discussions about the potential for fenebrutinib to be used across a broader population of PPMS patients [69][70] Conclusion Roche's ongoing developments in the MS treatment landscape, particularly with fenebrutinib and the Ocrevus franchise, highlight the company's commitment to addressing significant unmet medical needs in neurology. The promising results from the FENtrepid study and the strategic expansion of their product offerings position Roche favorably in the competitive landscape of MS therapies.

瑞银财富管理投资总监办公室（CIO）表示，中国市场具备增长与收益潜力。中国持续推动科技创新和 自立自强，为企业营造了有利的营商环境。同时，医疗保健企业"走出去"、新消费模式兴起及电网现代 化等利好，有望惠及医疗保健、消费、材料和电力设备等行业。 景顺中国内地及香港首席投资总监马磊表示："展望2026年，我们对中国股票市场继续保持乐观，持续 改善的基本面及长期增长动力有望打造一个更可持续的结构性增长周期。" 谈及中国股市的投资机会，马磊认为，一是产业升级。电动汽车、制药及自动化等关键行业有望推动下 一阶段的增长。拥有稳健研发实力的公司能够把握市场对先进产品及解决方案的需求。二是人工智能趋 势。2025年初发布的DeepSeek表明中国有能力提供兼具成本效益与高性能的大型语言模型，也标志着 中国已成为全球AI赛道一个强有力的竞争者。中国拥有全世界最大的互联网用户群之一，能源成本相 对较低，具备支持大规模人工智能发展和部署的基础条件。且中国大量的人才储备、庞大的数据资源， 以及高效的自动化扩展能力，赋予其将人工智能创新转化为实质生产力提升的竞争优势。三是消费演 变。受人口结构变化及消费者偏好持续演变的影响，未来中国 ...

Group 1: Market Overview - The three major U.S. stock indices opened lower, with the Dow Jones down 0.14%, while the Nasdaq rose by 0.11% and the S&P 500 increased by 0.18% [2] - A total of 2,267 stocks rose, while 2,884 stocks declined [2] Group 2: Pharmaceutical Sector - Novo Nordisk announced a lawsuit against Hims & Hers for patent infringement regarding the sale of compounded semaglutide products in the U.S., claiming misleading advertising about clinical benefits and safety [4] - Hims & Hers responded by stating that the lawsuit is an attack on millions of Americans relying on compounded medications for personalized treatment, asserting their commitment to consumer choice and affordability [4] Group 3: Stock Performance - Nvidia shares rose by 3.31%, reaching $191.54, with a market capitalization increase of approximately $477.74 billion over two trading days [5] - Other tech stocks like AMD and Microsoft also saw gains, while major companies like Apple and Amazon experienced declines [5][10] - AI application stocks showed a rebound, with Roblox increasing over 9%, Applovin up over 8%, and Unity Software rising nearly 8% [12]

Group 1: Market Overview - The three major U.S. stock indices opened lower, with the Dow Jones down 0.14%, while the Nasdaq rose 0.11% and the S&P 500 increased by 0.18% [1] - A total of 2,267 stocks rose, while 2,884 stocks declined [1] Group 2: Pharmaceutical Sector - Novo Nordisk announced a lawsuit against Hims & Hers for patent infringement regarding the sale of compounded semaglutide products in the U.S., claiming misleading advertising about clinical benefits and safety [3] - Hims & Hers responded by stating that the lawsuit attacks millions of Americans relying on compounded medications for personalized treatment, asserting their commitment to consumer choice and affordability [3] Group 3: Stock Performance - Nvidia shares rose by 3.31% to $191.54, with a market capitalization increase of approximately $477.74 billion (around 3.31 trillion RMB) over two trading days [3] - Other tech stocks such as AMD and Microsoft also saw gains, with AMD up over 3.15% and Microsoft up over 1.7%, while major companies like Google, Intel, Apple, and Amazon experienced declines [3][10] Group 4: AI Application Stocks - AI application stocks showed some rebound, with Roblox increasing over 9%, Applovin rising over 8%, and Unity Software up over 7.9% [10]

Group 1 - Novo Nordisk's stock rose over 6% and Eli Lilly's stock increased nearly 4% due to a lawsuit against Hims & Hers for infringing on the patent of semaglutide [3][4] - Hims & Hers' stock plummeted over 26% after the announcement of the lawsuit, which claimed that their competing product could pose potential dangers to consumers [3][4] - The FDA has indicated it will restrict the use of GLP-1 active ingredients in unapproved compounded drugs, which has been widely sold as alternatives to original drugs [3][4] Group 2 - Analyst Soren Lontoft Hansen from Sydbank noted that the rise in Novo Nordisk's stock reflects investor optimism regarding the FDA's crackdown on the compounded pharmaceutical industry [4] - The FDA's actions are seen as a direct challenge not only to Hims & Hers' compounded oral medication but also to the entire GLP-1 drug sector, benefiting both Novo Nordisk and Eli Lilly [4] - Since peaking in June 2024, Novo Nordisk's market value has evaporated by nearly two-thirds, with a cumulative decline of almost 50% over the past year [4]

| Hims & Hers Health Inc-A (Ai) [ Q | | | --- | --- | | HIMS | | | 16.350 16.923 >> | 17.825 最高 17.900 最低 | | 3.25亿 -26.49% -6.097 快手 | 8.05% 总量 1833万股 金额 | | 盘前 09:30 美东 V | 17.830 -5.190 -22.55% | | 国 年报预披露: 于2026-02-23(美东)盘后披露2025财年年报 ( ... ● | | | 均价:17.712 最新:16.923 -6.097 -26.49% | | | 29.561 | | | 300 9:36 16.950 | | | 9:36 16.950 141 | | | 23.020 - 9:36 16.9601 100 | | | 9:36 16.960 100 | | | 9:36 16.960 125 | | | 100 9:36 16.9234 | | | 9:36 16.940↑ 100 | | | 9:36 16.960↑ 500 | | | -28.42% 9:36 16.9 ...

Core Viewpoint - The company has received acceptance from the National Medical Products Administration (NMPA) for the regular approval of its drug, Envita (generic name: Envolimab injection), which was previously conditionally approved [1] Group 1 - The drug Envita is now transitioning from conditional approval to regular approval in the domestic market [1] - The application for regular approval was submitted by Sichuan Silu Kangrui Pharmaceutical Co., Ltd., a subsidiary of the company [1] - The acceptance number for the application is CYSB2600056, with the application specification being 200mg (1.0ml) per bottle [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 3D Medicines Inc. 思路迪医药股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1244） 自願公告 恩維達附條件批准轉常規批准補充申請獲 國家藥品監督管理局正式受理 本公告乃由思路迪医药股份有限公司（「本公司」，連同其附屬公司統稱為「本集 團」）自願作出。 本次申請由公司旗下四川思路康瑞藥業有限公司提交，申報材料於2026年2月2日 完成簽收並經審查予以受理。 關於恩維達® （通用名：恩沃利單抗注射液，原研代號：KN035） 恩維達® （通用名：恩沃利單抗注射液，原研代號：KN035）是重組人源化抗程序 性死亡配體1（「PD-L1」）單域抗體Fc融合蛋白。恩維達®由康寧傑瑞生物製藥（「康 寧傑瑞」，一間於2018年3月28日根據開曼群島法律註冊成立並於聯交所上市（股 份代號：9966）的獲豁免有限公司及其附屬公司（均為獨立第三方））自主研發， 2016年起與本公司合作開發。於 ...

凤凰网财经讯 2月9日，美股三大指数集体低开，纳指跌0.34%，道指跌0.25%，标普500指数跌0.24%。 减肥药概念股普涨，诺和诺德涨超5%，礼来涨超2%，因仿制司美格鲁肽而遭到诉讼的Hims & Hers则大 跌22%。存储概念股走弱，美光科技跌超3%。 公司消息 【黄仁勋力挺科技巨头超6000亿美元资本开支：需求旺盛 AI投资创造更多收入】 英伟达CEO黄仁勋在接受外媒采访时表示，科技行业在AI（人工智能）基础设施方面不断增长的资本 支出是合理、适当且可持续的，因为这些公司的现金流都将开始增长。包括微软、亚马逊、Meta、甲 骨文公司和Alphabet在内的科技巨头，正计划在2026年总计投入超过6000亿美元的资本支出。黄仁勋强 调，"人类历史上规模最大的基础设施建设"正在展开，其背后动力是对算力的"极度旺盛"的需求，AI公 司和超大规模云服务商正利用这些算力来创造更多收入。 【古尔曼：未来几周苹果将密集推出新产品】 科技记者马克·古尔曼（Mark Gurman）表示，苹果公司未来几周将推出一系列新产品，包括iPhone 17e、新款iPad，以及搭载M5 Pro/Max芯片的MacBook等。 ...